
Nov 2, 2026
Vor Biopharma (VOR) Reiterated at Buy by Stifel After Earnings, Corporate Update
Stifel analyst Stephen Willey reiterated a Buy rating and a $40.00 price target for Vor Biopharma (NASDAQ: VOR) following the company's earnings and corporate update. The article mentions this as premium content, requiring a subscription or login to view the full analysis.
Company relevance
100.00%
Company sentiment
Bullish
Overall sentiment
Bullish